雷替曲塞单药二线治疗老年晚期结直肠癌的临床研究.docxVIP

雷替曲塞单药二线治疗老年晚期结直肠 癌的临床研究 李翔罗良平万以叶姜莉 江西省肿瘤医院 摘要： 口的探讨雷替曲塞单药二线治疗老年晚期结直肠癌的疗效和安全性。方法将 57例老年晚期结直肠癌患者随机分为试验组(29例)和对照组(28例)。试验 组采用雷替曲塞单药方案化疗，对照组采用F0LF1R1方案化疗，观察并比较2 组治疗效果及不良反应。结果试验组与对照组的客观有效率(RR)分别为 13. 8%和17. 9%,疾病控制率(DCR)分别为58. 6%和53.6%,差异无统计学意义 (P0. 05)。2组屮位无进展生存时间(PFS)分别为4. 4个月和4. 9个月，差异 无统计学意义(P0. 05)。试验组在恶心、呕吐及腹泻方而的不良反应明显低于 对照组，差异有统计学意义(IK0.05)。结论雷替曲塞单药方案二线治疗老年 晚期结直肠癌疗效与FOLFIRI方案相当，且安全性更高，使用更方便。 关键词： 老年晚期结直肠癌;雷替曲塞;二线治疗; 收稿日期：2017-03-06 Clinical Study of Raltitrexed as Second-line Chemotherapy in the Treatment of Elderly Advanced Colorectai Cancer LI Xiang LUO Liangping WAN Yiye Jiangxi Cancer Hospital; Abstract： Objective To evaluate the efficacy and safety of raltitrexed as second-line chemotherapy for elderly advanced colorectal cancer. Methods 57 elderly patients with advanced colorectai cancer were randomly divided into the experiment group ( 29 cases) and the control group ( 28 cases). Paticnts in the experiment group received raltitrexed, the control group received chemotherapy with FOLF1RI, treatment effectiveness and adverse reactions were observed and compared. ResuIts The effective rates of the experiment group and the control group were 13. 8% and 17. 9%, respectively. The disease control rates of the experiment group and the control group of the experiment group was 4. 4 months，and m PFS of the was 4. 9 months. There were no significant differences in rates, disease control rates and median progression free between the 2 groups ( P 0. 05) . The incidence rate ofwere 58. 6% and 53. 6%, of the experiment group was 4. 4 months，and m PFS of the was 4. 9 months. There were no significant differences in rates, disease control rates and median progression free between the 2 groups ( P 0. 05) . The incidence rate of Keyword： Elderly advanced colorectal cancer; Raltitrexed; Second-line treatment; Received： 2017-03-06 结直肠癌是常见的消化道恶性肿瘤，全球每年有超过100万的新发病例，其中 约有50%最后发展为晚期。化疗是晚期结直肠癌的主要治疗手段。老年患者因其 机体机能状态减退，并且往往合并多种基础疾病，因此不能耐受强烈化疗，在 其一线治疗疾病进展后，二线化疗用药的选择就亟需平衡高效和低毒的关系。雷